Research programme: ATRN protein inhibitors - Atrin Pharmaceuticals

Drug Profile

Research programme: ATRN protein inhibitors - Atrin Pharmaceuticals

Alternative Names: Ataxia telangiectasia and Rad3-related protein inhibitors - Atrin Pharmaceuticals; ATRN 502; ATRN 507; ATRN-119

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atrin Pharmaceuticals
  • Developer Atrin Pharmaceuticals; University of Pennsylvania
  • Class Small molecules
  • Mechanism of Action ATR protein inhibitors; P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Apr 2016 Preclinical trials in Cancer in USA (PO) prior to April 2016
  • 16 Apr 2016 Pharmacodynamics data from preclinical trials in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top